NSF Makes It Easier To Appeal As It Opens Up Review Process

WASHINGTON -- The National Science Foundation, in the midst of declining funding rates and a growing debate about the nature of peer review, has decided to make it easier for scientists to appeal the bad news they receive. Procedural changes disclosed last month at a meeting of the National Science Board also are designed to help NSF identify the worthiest grant proposals and to provide applicants with more information about the factors that led to funding decisions. "We want to open up the pr

Written byJeffrey Mervis
| 4 min read

Register for free to listen to this article
Listen with Speechify
0:00
4:00
Share

WASHINGTON -- The National Science Foundation, in the midst of declining funding rates and a growing debate about the nature of peer review, has decided to make it easier for scientists to appeal the bad news they receive. Procedural changes disclosed last month at a meeting of the National Science Board also are designed to help NSF identify the worthiest grant proposals and to provide applicants with more information about the factors that led to funding decisions.

"We want to open up the process to the outside," NSF Director Erich Bloch told board members. "We want the PIs [principal investigators] to feel free to say what they think. And we also want to tell them as much as possible about how the decision [on their proposal] was made."

Critics of what NSF officials call merit review say they welcome the changes. They also claim partial credit for them. Last summer ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies